Clinical Trials on Kallmann Syndrome

Total 33934 results

argenx

Recruiting

A Natural History Study in Participants With DOK7 Congenital Myasthenic Syndromes (CMS)

Congenital Myasthenic Syndrome

Spain, France, United States, Canada
Catalyst Pharmaceuticals, Inc.

Completed

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

Myasthenic Syndromes, Congenital

United States
Mayo Clinic

Completed

Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes

Congenital Myasthenic Syndrome

United States
Institut de Myologie, France
Assistance Publique - Hôpitaux de Paris

Completed

Pregnancy Outcomes in Congenital Myasthenie Syndrome (POCoMS)

Congenital Myasthenic Syndrome
Jinling Hospital, China

Completed

Nonthyroidal Illness Syndrome in SBS

Short Bowel Syndrome | Nonthyroidal Illness Syndrome
Rockefeller University

Completed

Immunotherapy of the Paraneoplastic Syndromes

Paraneoplastic Syndromes

United States
Dafne Balemans
Grünenthal GmbH

Completed

taPentadol cLinical prAcTice IN belgiUM (PLATINUM)

Severe Pain Syndromes

Belgium
Assistance Publique - Hôpitaux de Paris

Completed

Immunotherapy and Paraneoplastic Neurological Syndromes (IaSON)

Paraneoplastic Neurological Syndromes

France
Universitaire Ziekenhuizen KU Leuven

Completed

Study to Assess Safety and Efficacy of sc Pasireotide in Patients With Dumping Syndrome (CSOM230BBE01T)

Postoperative Dumping Syndrome

Belgium
Guang'anmen Hospital of China Academy of Chinese...
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; China Food...

Completed

The Efficacy and Safety of the Xue-Fu-Zhu-Yu Capsule in Treatment of Qi Stagnation and Blood Stasis Syndrome. (TROTEASOTXZC)

Qi Stagnation and Blood Stasis Syndrome

China
Technological Educational Institute of Thessaly

Recruiting

Fat Supplementation on Dumping Syndrome Associated Symptoms (Fat on DS)

Dumping Syndrome

Greece
Radboud University Medical Center

Unknown

Treatment of the Dumping Syndrome With Lanreotide Autogel®

Dumping Syndrome

Netherlands
Universitaire Ziekenhuizen KU Leuven
Ipsen

Completed

SOMATULINE Autogel 90 mg IN DUMPING SYNDROME

Dumping Syndrome

Belgium
Novartis Pharmaceuticals

Completed

Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome

Dumping Syndrome

Belgium, Netherlands, Germany, France, United States
National Pediatric Neuroinflammation Organization...

Completed

Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome (OMS)

Opsoclonus-myoclonus Syndrome

United States
Axogen Corporation

Recruiting

Nerve Protection Evaluation: Revision Cubital Tunnel Syndrome Decompression (COVERED)

Recurrent Cubital Tunnel Syndrome | Recalcitrant Cubital Tunnel Syndrome

United States
National Pediatric Neuroinflammation Organization...
Genentech, Inc.

Completed

Effectiveness of Rituximab in Pediatric OMS Patients.

Ataxia | Myoclonus | Opsoclonus-myoclonus Syndrome | Opsoclonus

United States
University of Florida

Completed

Retrospective Analysis of Treatment Outcomes in Patients With Bacterial Overgrowth Syndrome Diagnosed by D-Xylose Breath Testing (SIBO)

Small Intestinal Bacterial Overgrowth Syndrome (SIBO) | Small Bowel Bacterial Overgrowth Syndrome (SBBOS)

United States
Ruhr University of Bochum
Wissenschaftskommission des Universitaetsklinikums Bergmannsheil; Private Sponsor...

Unknown

Approach to a Quantitative Follow-up of Non-thyroidal Illness Syndrome (AQUA FONTIS)

Euthyroid Sick Syndromes | Non-thyroidal Illness Syndrome | Low T3 Syndrome | TACITUS

Germany
Laboratorios Sophia S.A de C.V.

Completed

Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Ultra Preservative Free (087LATAMFIV) (087LATAMFIV)

Dry Eye Syndrome

Mexico
Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

Japan
Fondazione Italiana Sindromi Mielodisplastiche-ETS

Recruiting

Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care (FISiM-NGS-MDS)

MDS (Myelodysplastic Syndrome)

Italy
Novartis Pharmaceuticals

Active, not recruiting

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Myelodysplastic Syndrome (MDS)

United States
Fujifilm Pharmaceuticals U.S.A., Inc.

Withdrawn

A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Safety of ON 01910.Na in Patients With Myelodysplasia

Myelodysplastic Syndrome (MDS)

United States
Telik

Terminated

Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

United States
Oncology Specialties, Alabama

Terminated

Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)

United States
Groupe Francophone des Myelodysplasies
Bristol-Myers Squibb; AbbVie

Recruiting

Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes

Untreated Myelodysplastic Syndrome

France
Case Comprehensive Cancer Center

Recruiting

CPX-351 Therapy for MDS After Hypomethylating Agent Failure

Myelodysplastic Syndrome (MDS)

United States
Novartis Pharmaceuticals

Completed

A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants (STIMULUS-MDS3)

Myelodysplastic Syndrome (MDS)

France, Spain, Belgium, Italy, Greece, Hungary, Germany
Weill Medical College of Cornell University
Novartis Pharmaceuticals

Completed

MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions (T2*MRI)

Myelodysplastic Syndrome (MDS)

United States
Incyte Corporation

Terminated

Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)

MDS (Myelodysplastic Syndrome)

United States
Chinese Society of Hematology
Harbin Institute of Hematology & Oncology

Unknown

Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study (MD-CHINA)

Myelodysplastic Syndrome (MDS)
Asociación Andaluza de Hematología y Hemoterapia

Completed

Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia (ABRAZA)

Myelodysplastic Syndrome (MDS)

Spain
Genzyme, a Sanofi Company

Terminated

Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome (RISE)

Myelodysplastic Syndrome (MDS)

Germany, United Kingdom, France, Netherlands
Heinrich-Heine University, Duesseldorf

Terminated

Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome (VALENA)

Myelodysplastic Syndrome MDS

Germany
Telik

Terminated

Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

United States
Telik

Completed

Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)

United States
Seagen Inc.

Completed

A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome (MDS)

United States
zhang shoulong
Changhai Hospital; Jinan Military General Hospital

Recruiting

Biomarker and Imaging Package Study in Immune Effector Cell-Associated Neurotoxicity Syndrome

Immune Effector Cell Associated Neurotoxicity Syndrome

China
AbbVie
Genentech, Inc.

Active, not recruiting

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona)

Myelodysplastic Syndrome (MDS)

United States, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Puerto Rico, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
Amphivena Therapeutics, Inc.

Completed

A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes

Myelodysplastic Syndrome (MDS)

United States
Celgene

Completed

Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

China
Amgen

Completed

Darbepoetin Alfa MDS Companion Protocol

Myelodysplastic Syndrome (MDS)

Belgium
Novartis Pharmaceuticals

Terminated

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) (GEPARD)

Myelodysplastic Syndrome (MDS)

Germany
Telik

Completed

Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)

United States
Thomas Jefferson University
AbbVie

Recruiting

Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome

Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic Syndrome

United States
University of Wisconsin, Madison

Terminated

Botox for the Treatment of Chronic Exertional Compartment Syndrome

Compartment Syndrome of Leg

United States
Scripps Health
J. Craig Venter Institute

Completed

Biomarker Monitoring in TP53 Mutation Carriers

Li-Fraumeni Syndrome | Hereditary Cancer Syndromes | TP53 Gene Germline Mutation Carrier

United States
Erasmus Medical Center

Enrolling by invitation

Long-term Pain Modulation by Intravenous Esketamine in CRPS (KetCRPS-2)

Complex Regional Pain Syndromes | CRPS (Complex Regional Pain Syndromes)

Netherlands

Clinical Trials on Kallmann Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations